StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
INBXInhibrx Biosciences, Inc.
stockpulse.co.kr
Nasdaq
$93.19▲ 0.11%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.37BShares out 14.7M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

21
  • 10.14After-hours26.10.15 07:58
    4Ownership#●●●

    Inhibrx Biosciences, Inc.

    Mark Lappe, an insider of Inhibrx Biosciences, Inc., reported a change in beneficial ownership of securities on October 14, 2026. This filing serves as an official disclosure of the insider's equity position change to the SEC.…more

    $93.19+0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.28After-hours26.09.29 06:47
    4Ownership

    Inhibrx Biosciences, Inc.

    Inhibrx Biosciences, Inc. insider Mark Lappe has filed a Form 4 report regarding changes in beneficial ownership of securities as of September 25, 2026. This filing serves as a standard disclosure of changes in the executive's stock holdings.…more

    $93.19+0.11%vs prev close
    View filingShare
  • 9.28After-hours26.09.29 06:03
    8-KKey event

    Inhibrx Biosciences, Inc.

    Inhibrx Biosciences, Inc. reported $219.5 million in cash and cash equivalents and 14.7 million shares of common stock outstanding as of August 6, 2026. The company released an updated corporate presentation detailing interim Phase 2 clinical data for INBRX-106 and outlining its upcoming Phase 3 clinical development strategy.…more

    $93.19+0.11%vs prev close
    View filingShare

20 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.8Regular26.09.09 00:29
    #●●●#●●●

    Inhibrx Biosciences Reports Positive Phase 2 Results for Cancer Drug

    Inhibrx Biosciences' drug candidate showed superior objective response rates in a Phase 2 trial when combined with Keytruda. Despite the positive clinical data, the company's stock price experienced a decline.…more

    $93.19+0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.8Pre-market26.09.08 20:55

    ●●●●●●●● ●●●●● ●●●●●●

    A trading halt on a specific stock has been lifted, and quotation has resumed. The resumption follows the release of news regarding the company.…more

    $93.19+0.11%vs prev close
    ShareBenzinga
  • 9.8Pre-market26.09.08 20:25

    ●●●●●●●● ●●●●● ●●●●●●

    Trading for this security has been temporarily halted pending the release of material news. Investors should monitor for upcoming official announcements.…more

    $93.19+0.11%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →